BioLineRx Ltd.
BLRX
$2.73
-$0.21-7.14%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Net Income | -1,302.89% | 169.54% | 94.99% | 13.35% | 13.60% |
| Total Depreciation and Amortization | 76.47% | -46.93% | 38.64% | 192.76% | 11.62% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 72.29% | -43.64% | -202.22% | -26.83% | -50.76% |
| Change in Net Operating Assets | 52.33% | 33.11% | -173.24% | 1,159.08% | 223.21% |
| Cash from Operations | 13.28% | 19.70% | -382.69% | 150.41% | -2.26% |
| Capital Expenditure | 100.00% | 15.63% | -100.00% | -1,500.00% | 98.51% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 218.07% | -151.55% | 182.04% | -597.29% | -63.30% |
| Cash from Investing | 217.70% | -151.81% | 181.82% | -597.80% | -63.09% |
| Total Debt Issued | -100.00% | -- | -- | -- | -- |
| Total Debt Repaid | -14.19% | -1.68% | -3.59% | 8.39% | -602.99% |
| Issuance of Common Stock | -- | -- | -- | 183.79% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -105.10% | 2,771.03% | -107.61% | 235.52% | 2,711.19% |
| Foreign Exchange rate Adjustments | 129.78% | -633.33% | -73.44% | 366.67% | 70.73% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -121.66% | 109.39% | 149.97% | -46.07% | -329.00% |
